Efficacy and Side Effects of Generic (Osloda®) and Brand-Name (Xeloda®) Capecitabine in Metastatic Breast Cancer
Published: 2020-06-22
Page: 77-83
Issue: 2020 - Volume 3 [Issue 1]
Parastoo Hajian
Department of Radiation Oncology, Cancer Research Center, Shohadae Tajrish Hospital, Shahid Beheshti University of Medical Sciences, Iran.
Farnaz Tabatabaie
Discipline of Physics, School of Science, RMIT University, Melbourne, Australia.
Hamidreza Mirzaei *
Department of Radiation Oncology, Cancer Research Center, Shohadae Tajrish Hospital, Shahid Beheshti University of Medical Sciences, Iran.
*Author to whom correspondence should be addressed.
Abstract
Purpose: To compare the efficacy and side effects of brand-name capecitabine (Xeloda®) vs. generic (Osloda®) in metastatic breast cancer.
Methods: In this non-randomized clinical trial, 39 patients with metastatic breast cancer were included and divide into Xeloda® (19 patients, mean age of 49.5 years) or Osloda® (20 patients, mean age of 51.7 years) groups. A total of six 3-week cycles (1250 mg/m2 daily) were administered. Efficacy and side effects were documented in a three-year follow-up period.
Results: The four most common treatment-related adverse events did not differ significantly in Xeloda group vs. Osloda group including hand-foot syndrome (68.4% vs. 65%, P= 0.82), Anorexia (47.4% vs. 50%, P= 0.86), pain (57.9% vs. 40%; P= 0.26), and nausea (52.6% vs. 35%; P= 0.26). Most patients in both groups (25 subjects) showed partial response. Nine patients in each group died (47.4% in Xeloda group and 45% in Osloda group, P= 0.88). Mean overall survival was 20.13 months in Xeloda group and 25.82 months in Osloda group (P= 0.47).
Conclusion: Xeloda and Osloda had comparable efficacy and side effects in metastatic breast cancer. Considering the lower cost of Osloda, this agent can be used instead of Xeloda.
Keywords: Capecitabine, breast cancer, metastasis, adverse event, side effect, efficacy